

HR 8467

Access to Rare Indications Act of 2020

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Sep 30, 2020

Current Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

Latest Action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (Sep 30, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/8467>

Sponsor

Name: Rep. Thompson, Mike [D-CA-5]

Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Kelly, Mike [R-PA-16]	R · PA		Sep 30, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Sep 30, 2020
Ways and Means Committee	House	Referred To	Sep 30, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Sep 30, 2020)

Access to Rare Indications Act of 2020

This bill prohibits coverage exclusions or limitations under the Medicare prescription drug benefit, Medicaid, or private health insurance of certain drugs that are used to treat rare diseases or conditions (i.e., diseases or conditions that affect 200,000 or fewer individuals and that are supported by the National Institutes of Health Rare Diseases Clinical Research Network).

Actions Timeline

- **Sep 30, 2020:** Introduced in House
- **Sep 30, 2020:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.